Results 11 to 20 of about 2,887 (179)

Olmesartan medoxomil: current status of its use in monotherapy

Vascular Health and Risk Management, 2006
Hans R BrunnerLausanne University, Lausanne and Medizinische Poliklik, Universitaetsspital, Basel, SwitzerlandAbstract: Olmesartan medoxomil is an angiotensin II receptor antagonist.
Hans R Brunner
doaj   +1 more source

Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension

Vascular Health and Risk Management, 2006
Mark GreathouseSouth Hills Cardiology Associates of Pittsburgh, Pittsburgh, PA, USAAbstract: In most patients with hypertension, especially Stage 2 hypertension, adequate control of blood pressure (BP) is only achieved with combination drug therapy. When
Mark Greathouse
doaj   +1 more source

Combined treatment with olmesartan medoxomil and amlodipine besylate attenuates atherosclerotic lesion progression in a model of advanced atherosclerosis

Drug Design, Development and Therapy, 2015
Philipp Sievers,1 Lorenz Uhlmann,2 Sevil Korkmaz-Icöz,3 Christian Fastner,1 Florian Bea,1 Erwin Blessing,1 Hugo A Katus,1 Michael R Preusch11Department of Internal Medicine III, 2Institute of Medical Biometry and Informatics, 3Department of ...
Sievers P, Uhlmann L, Korkmaz-Icöz S, Fastner C, Bea F, Blessing E, Katus HA, Preusch MR   +7 more
doaj   +1 more source

ANTIHYPERTENSIVE EFFICACY OF OLMESARTAN MEDOXOMIL, A NEW ANGIOTENSIN II RECEPTOR ANTAGONIST, AS ASSESSED BY AMBULATORY BLOOD PRESSURE MEASUREMENTS

Российский кардиологический журнал, 2011
Olmesartan medoxomil is a new angiotensin II receptor blocker. In this randomized, double-blind, placebo-controlled study, the efficacy and safety of olmesartan medoxomil was assessed in 334 patients with moderate to severe essential hypertension ...
J. M. Neutel, W. J. Elliott, J. L. Izzo, C. L. Chen, H. N. Masonson   +4 more
doaj   +1 more source

EVALUATION OF ANTIHYPERTENSIVE THERAPY WITH THE COMBINATION OF OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

Российский кардиологический журнал, 2011
Most patients with hypertension require more than one agent to control blood pressure (BP). The purpose of this study was to assess the efficacy and safety of the angiotensin II receptor blocker olmesartan medoxomil in combination with ...
Steven G. Chrysant, Michael A. Weber, Antonia C. Wang, Donald J. Hinman   +3 more
doaj   +1 more source

Application of a Stability-Indicating HPTLC Method for Simultaneous Quantitative Determination of Olmesartan Medoxomil and Hydrochlorothiazide in Pharmaceutical Dosage Forms [PDF]

Journal of Analytical Methods in Chemistry, 2013
A rapid, precise, sensitive, economical, and validated high performance thin layer chromatographic method is developed for simultaneous quantification of olmesartan medoxomil and hydrochlorothiazide in combined tablet dosage form.
Kaliappan Ilango, Pushpangadhan S. Shiji Kumar   +1 more
doaj   +2 more sources

Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil

Vascular Health and Risk Management, 2009
Carlos FerrarioHypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, NC, USAAbstract: Endothelial dysfunction is the common link between cardiovascular disease risk factors and the earliest event in the ...
Carlos Ferrario
doaj   +1 more source

Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong)

Drug Design, Development and Therapy, 2016
Jin-Sun Park,1,* Joon-Han Shin,1,* Taek-Jong Hong,2 Hong-Seog Seo,3 Wan-Joo Shim,4 Sang-Hong Baek,5 Jin-Ok Jeong,6 Youngkeun Ahn,7 Woong-Chol Kang,8 Young-Hak Kim,9 Sang-Hyun Kim,10 Min-Su Hyon,11 Dong-Hoon Choi,12 Chang-Wook Nam,13 Tae-Ho Park,14 Sang ...
Park JS, Shin JH, Hong TJ, Seo HS, Shim WJ, Baek SH, Jeong JO, Ahn YK, Kang WC, Kim YH, Kim SH, Hyon MS, Choi DH, Nam CW, Park TH, Lee SC, Kim HS   +16 more
doaj   +1 more source

Gastroretentive microballoons of olmesartan medoxomil: formulation and <i>in vitro-in vivo</i> evaluation. [PDF]

Ther Deliv
BACKGROUND: Olmesartan medoxomil, classified as BCS class II due to its poor water solubility, exhibits a low oral bioavailability of 28.6%. MATERIALS AND METHODS: Microballoons of Olmesartan medoxomil were formulated using the ionotropic gelation ...
Patil AS, Aloshi S, Gaude Y, Masareddy RS.   +3 more
europepmc   +2 more sources

Benzbromarone as a Novel Candidate for Preventing Alzheimer's Disease: Evidence From Real-World Data Screening and in Vitro Validation. [PDF]

Clin Transl Sci
Drug repositioning analysis identifies candidate therapeutic agents for Alzheimer’s diseaseand supports further mechanistic and translational investigation. ABSTRACT Drug development for Alzheimer's disease (AD) remains challenging, with only a 0.4% success rate from Phase I trials to regulatory approval.
Sakagami S, Yoshida Y, Uemura S, Kumamoto T, Tsukamoto R, Nishi T, Kawano S, Fukuoka K, Ino H, Hamamura K, Ohdo S, Matsunaga N.   +11 more
europepmc   +2 more sources